GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » COGS-to-Revenue

Mega Genomics (HKSE:06667) COGS-to-Revenue : 0.35 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics COGS-to-Revenue?

Mega Genomics's Cost of Goods Sold for the six months ended in Jun. 2024 was HK$40.6 Mil. Its Revenue for the six months ended in Jun. 2024 was HK$115.5 Mil.

Mega Genomics's COGS to Revenue for the six months ended in Jun. 2024 was 0.35.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Mega Genomics's Gross Margin % for the six months ended in Jun. 2024 was 64.89%.

Mega Genomics COGS-to-Revenue Historical Data

The historical data trend for Mega Genomics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics COGS-to-Revenue Chart

Mega Genomics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
0.37 0.28 0.30 0.44 0.42

Mega Genomics Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only 0.34 0.64 0.34 0.56 0.35

Mega Genomics COGS-to-Revenue Calculation

Mega Genomics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=68.913 / 165.489
=0.42

Mega Genomics's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=40.556 / 115.503
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mega Genomics  (HKSE:06667) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Mega Genomics's Gross Margin % for the six months ended in Jun. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 40.556 / 115.503
=64.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Mega Genomics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mega Genomics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Genomics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » COGS-to-Revenue
Comparable Companies
HKSE:09960 HKSE:02325 HKSE:08037 HKSE:02427 HKSE:08225 HKSE:00928 HKSE:08247 HKSE:09860 TMO DHR XSWX:LONN IDXX A SHSE:603259 IQV MTD NTRA WAT LH DGX
Traded in Other Exchanges
N/A
Address
North Garden Road, 401 Health Work, Haidian District, Beijing, CHN
Website
https://www.megagenomics.cn
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
Executives
Dongyin Industrial (shenzhen) Co., Ltd. 2106 Person having a security interest in shares
Dongyin (tianjin) Enterprise Management Consulting Co., Ltd. 2106 Person having a security interest in shares
Dongfu Hetong (tianjin) Equity Investment Fund Partnership Enterprise (limited Partnership) 2106 Person having a security interest in shares
Yurong Technology Limited 2101 Beneficial owner
Dongfu (beijing) Investment Management Co., Ltd. 2106 Person having a security interest in shares
Dong Yin Development (holdings) Limited 2106 Person having a security interest in shares
China Orient Asset Management Co., Ltd. 2106 Person having a security interest in shares
Beijing Dongfu Huitong Investment Management Center (limited Partnership) 2106 Person having a security interest in shares
Guo Meiling 2101 Beneficial owner
Yu Rong 2501 Other
Lin Lin 2101 Beneficial owner
Infinite Galaxy Health Limited 2101 Beneficial owner
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si 2501 Other

Mega Genomics Headlines

No Headlines